Annahita Keravala

Company: Genascence Corporation

Job title: Co-Founder & CSO

Bio:

Annahita Keravala, PhD has 25 years of experience in gene therapy with 12+ years in industry. She has deep expertise in overseeing all functions of gene therapy product development, including molecular biology, CMC, assay development, etc. in start-up biotech and has moved several gene therapy programs from early discovery through pre-clinical to the clinic.

Seminars:

Transferable Lessons from Treating Rare Diseases with Gene Therapies 10:00 am

Genascence’s approach to developing gene therapies for prevalent diseases Discussing the commercial viability of making expensive therapies more accessible to a large patient population Applying the lessons learnt when manufacturing gene therapies for rare diseases to manufacturing processes for larger disease indicationsRead more

day: Gene Therapy Beyond Rare Diseases Discussion Day